1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow LY4052031: new trials by email Literature Review of LY4052031 trials Research Report on LY4052031
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors LY4052031, Pembrolizumab - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2024-07-01 | 2026-10-22 |
Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Ureteral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urologic Neoplasms (1) · Uterine Cervical Neoplasms (1)
Australia (1) · China (1) · France (1) · Japan (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)